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Abstract
Background: Microglia might play an important role in nociceptive processing and hyperalgesia by neuroinflammatory
process. Mineralocorticoid receptor (MR) expressed on microglia might play a central role in the modulation of microglia
activity. However the roles of microglia and MR in radicular pain were not well understood. This study sought to investigate
whether selective MR antagonist spironolactone develop antinociceptive effects on radicular pain by inhibition
neuroinflammation induced by spinal microglia activation.
Results: Radicular pain was produced by chronic compression of the dorsal root ganglia with SURGIFLO
TM. The expression
of microglia, interleukin beta (IL-1b), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-a), NR1 subunit of the NMDA
receptor (t-NR1), and NR1 subunit phosphorylated at Ser896 (p-NR1) were also markedly up-regulated. Intrathecal injection
of spironolactone significantly attenuated pain behaviors as well as the expression of microglia, IL-1b, TNF-a, t-NR1, and p-
NR1, whereas the production of IL-6 wasn’t affected.
Conclusion: These results suggest that intrathecal delivery spironolactone has therapeutic effects on radicular pain in rats.
Decreasing the activation of glial cells, the production of proinflammatory cytokines and down-regulating the expression
and phosphorylation of NMDA receptors in the spinal dorsal horn and dorsal root ganglia are the main mechanisms
contributing to its beneficial effects.
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Introduction
Chronic low back pain is a significant clinical problem for which
current treatments are inadequate [1]. This is due in large part to
the fact that the mechanisms underlying neuropathic allodynia
and hyperalgesia are insufficiently understood. Increasing evidence
strongly implicates a role for spinal glia and proinflammatory
cytokines, such as IL-1b, TNF-a and IL-6, in the genesis or
maintenance of persistent pain via central mechanism [2–5].
Microglial cells are the innate immune cells of the central nervous
system, they respond quickly to injury and produce a wide variety
of proinflammatory molecules, neurotrophic factors, and neuro-
transmitters [6]. Mounting evidence indicates that microglia
actively communicate with neurons and are important contribu-
tors in the development of neuropathic pain [7–8]. Spinal
expressions of IL-1b, TNF-a, and IL-6 are elevated in association
with pain facilitation [5] and intrathecal administration of
cytokines also produce allodynia, hyperalgesia and changes in
spinal cord neuronal responses to nociceptive stimuli in the rat [9].
Revealed by both western blot experiments and patch-clamp
recordings, activated microglia and proinflammatory cytokines
increased the expression and phosphorylation of NMDA receptor,
enhanced NMDA-induced currents and contributed to neuro-
pathic pain and proinflammatory pain [3,4,10,11,28]. Our
previous study also found a remarkable inflammatory process in
the spinal dorsal horn and dorsal root ganglia (DRG) after chronic
compression of dorsal root ganglia in rats [12]. In addition,
intrathecal therapy with anti-inflammatory prednisolone acetate
inhibited pain behaviors and the upregulation of neuronal nitric
oxide synthase (nNOS) and NMDA receptor in the spinal dorsal
horn [13].
NMDA receptors are heteromeric complexes incorporating
different subunits chosen within a repertoire of three subtypes:
NR1, NR2 and NR3. Of particular importance is the high
permeability to calcium ions, which confers on NMDA receptors
a central role in synaptic plasticity [14]. Numerous studies have
reported that the expression and activation of NMDA receptors in
the spinal dorsal horn play a crucial role in the development and
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studies also found that there were marked increases in the
expression of NMDA receptor in the superficial dorsal horn and
DRG after chronic compression of the dorsal root ganglia
[12,13,19]. Intrathecal injection of NMDA receptor antagonist
ifenprodil attenuated thermal hyperalgesia and mechanical
allodynia induced by chronic compression of the dorsal root
ganglia or bone cancer [19,20].
Spironolactone is a competitive aldosterone receptor antago-
nist used for over 40 years to treat diseases associated with
primary or secondary hyperaldosteronism [21]. Growing pre-
clinical and clinical evidences suggest that treatment of
microglia with GCs decreases the ability of these cells to
proliferate [22], to produce proinflammatory cytokines [23].
Evidence suggests that spironolactone inhibits production of
several proinflammatory cytokines, including TNF-a and IL-1b
via mineralocorticoid receptor or non-mineralocorticoid receptor
mechanisms and show positive effects in patients with
immunoinflammatory diseases [24–27]. An in vivo study showed
that corticosterone and aldosterone at concentrations lower than
1 nM enhanced the activities of microglial cells which could be
reversed by spironolactone [28]. Frieler et al. found that MR
knockout resulted in significant reduction in activated microglia,
the production of proinflammatory cytokines and infarct volume
after middle cerebral artery occlusion [29]. Recent studies
shown that spironolactone exerts therapeutic effects on neuro-
pathic pain and capsaicin-induced chemogenic pain [30,31]. In
light of these reports, it is possible that spironolactone may
inhibit the activation of spinal glial cells and decrease the
production of proinflammatory cytokines. Subsequently, the
expression and function of NMDA receptors in the spinal dorsal
horn were affected. Our previous studies also found that
intrathecal delivery of spironolactone has therapeutic effects on
radicular pain [32].
In our present study, we examined the hypothesis that
spironolactone inhibits the activation of glial cells and the
production of proinflammatory cytokines, the expression and
phosphorylation of NMDA receptor in spinal dorsal horn and
DRG, and exerts beneficial effects on pain behaviors in a rat
model of radicular pain induced by chronic compression of
lumbar dorsal root ganglia with SURGIFLO
TM.
Results
Intrathecal Injection of Spironolactone Improves Pain
Behaviors after CCD Surgery
Consist with our previous study, both mechanical allodynia
(Figure 1A) (P,0.001) and thermal hyperalgesia (Figure 1B)
(P,0.001) were observed on the ipsilateral side following CCD
surgery and lasted up to at least 21 days. Spironolactone (3 mg),
minocycline (0.11 mg), spironolactone (3 mg) with half-hour pre-
application minocycline (0.11 mg) were administered intrathe-
cally twice a day from Days 2 to 4 subsequent to CCD surgery
significantly reduced paw withdrawal mechanical threshold on
Day 4 [(12.0561.19) g, (12.9960.58) g, (12.7760.78) g ] VS
(7.5160.88) g, P,0.01, and Day 7 [(11.1061.62) g,
(12.2060.66) g, (11.7861.46) g ] VS (7.4161.06) g, P,0.01
(Figure 1A) as well as paw withdrawal thermal latency on Day 4
[(14.2961.61) s, (16.9961.58) s, (17.7161.48) s ] VS
(8.9661.43) s, P,0.01, and Day 7 [(12.3961.62) s,
(15.2061.66) s, (15.7861.46) s] VS (7.9761.84) s, P,0.01
(Figure 1B) in comparison to vehicle-treated CCD rats. The
selected spironolactone dose has been proven to have analgesic
effect in CCD rats [36]. However, no significant difference was
found on the contralateral side and between the minocycline
(0.11 mg) and spironolactone (3 mg) with half-hour pre-applica-
tion minocycline (0.11 mg) (P.0.05, data not shown). Based on
these obtained results we come to the conclusion that
spironolactone plays a pivotal role in relieving pain hypersen-
sitivity via inactivation of microglia in our animal model.
Intrathecal Injection of Spironolactone Inhibits the
Expression of Microglia in the Spinal Dorsal Horn
Figure 2 and 3 illustrated the changes in the expression of
microglia in spinal dorsal horn after CCD surgery and the time-
course effects of spironolactone. To test whether the activation of
microglia in the spinal dorsal horn, we performed immunostaining
Figure 1. Intrathecal injection of spironolactone (Spir) improves pain behaviors after CCD surgery (n=6/each). D0, 1, 4, 7, 10, 14, 17
and 21 indicate days of CCD. All data points represent mean6SD. Compared with sham group, chronic compression of the dorsal root ganglion (CCD)
significantly decreased paw withdraw mechanical threshold (PWMT) (A) and thermal latency (PWTL) (B),
*P,0.01. Both mechanical allodynia (A) and
thermal hyperalgesia (B) were diminished in CCD rats treated with spironolactone (3 mg), minocycline (0.11 mg) and spironolactone (3 mg) with half-
hour pre-application minocycline (0.11 mg) twice a day from Days 2 to 4 subsequent to CCD surgery,
#P,0.01.
doi:10.1371/journal.pone.0039897.g001
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contralateral, the microglia marker OX-42 was significant increase
in spinal cord sections, which were ipsilateral to the CCD surgery
(Fig. 2D). Compared with the sham rats (Fig. 2A and 2A’), the
activated microglia cells typically exhibited hypertrophy with
thicker processes, larger and densely stained cell bodies after CCD
surgery (Fig. 2B and 2B’). Injection of spironolactone inhibited
microglia activation (Fig. 2C and 2C’). The upregulation of OX-
42 was quantified by Western blot. The tissues from the spinal
cord sections were punched out, and total proteins were isolated.
As shown in Figure 3, consistent with pain behaviors, remarkable
up-regulation of microglia was observed after CCD surgery in the
spinal dorsal horn (Figure 3A–B). Intrathecal delivery of
spironolactone significantly suppressed the expression of microglia
on Day 4 [(0.6760.10) VS (1.1860.12), P=0.016] and Day 7
[(1.0260.17) VS (1.5660.13), P=0.026].
Spironolactone Inhibits the Production of
Proinflammatory Cytokines in the Spinal Dorsal Horn
and DRG
Figure 4 and 5 illustrated the changes in the expression of
proinflammatory cytokines in spinal dorsal horn and DRG after
CCD surgery and the time-course effects of spironolactone.
Consistent with pain behaviors, remarkable up-regulation of IL-
1b, IL-6 and TNF-a were observed after CCD surgery in the
spinal dorsal horn and DRG (Figure 4A–B and 5A–B). Intrathecal
delivery of spironolactone significantly suppressed the production
of IL-1b and TNF-a on Day 4 [IL-1 b: (0.1160.06) VS
(0.5060.16), P=0.019; TNF-a: (0.1660.03) VS (0.8760.17),
P=0.002], [IL-1b: (0.2260.09) VS (0.5860.11), P=0.026; TNF-
a: (0.2360.04) VS (1.0760.15), P=0.001] and Day 7 [IL-1 b:
(0.7060.15) VS (1.1060.11), P=0.020; TNF-a: (0.6160.10) VS
Figure 2. Immunohistochemistry showed the effects of intrathecal injection of spironolactone on activation of microglia in the
spinal dorsal horn (n=3/each). Quantification of microglia activation after CCD surgery. Confocal images of sham (A and A’), Day 4 after CCD
surgery (B, B’ and D), Day 4 after injection of spironolactone (C and C’), showing the increase in the microglia marker OX-42 in L4 spinal cord sections,
the activated microglia cells typically exhibited hypertrophy with thicker processes, larger and densely stained cell bodies after CCD surgery. Injection
of spironolactone inhibited microglia activation.
doi:10.1371/journal.pone.0039897.g002
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P=0.019; TNF-a: (0.7360.08) VS (1.1160.12), P=0.015], while
no notable effect was seen on the expression of IL-6 (P.0.05)
(Figure 4A, 4C and 5A, 5C ).
Spironolactone Decreases the Expression and
Phosphorylation of NMDA Receptor
It has been reported that proinflammatory enhanced excitatory
synaptic transmission was one of the main mechanisms involved in
central sensitization [3,4]. Thus we further examined the
expression and phosphorylation of NMDA receptor in spinal
dorsal horn and DRG. Congruous with pain behaviors and the
expression of proinflammatory cytokines, there were marked
elevation of total NR1 (t-NR1) and phosphor-NR1 at Ser896 (p-
NR1) in spinal dorsal horn and DRG after CCD surgery. When
treated with spironolactone, as shown in figure 6 and 7, the
expression of t-NR1 and p-NR1 were significantly decreased on
Day 4 [t-NR1: (0.3060.02) VS (0.6360.09), P=0.004; p-NR1:
(0.2360.09) VS (0.5360.08), P=0.012], [t-NR1: (0.4660.03) VS
(0.7060.07), P=0.005; p-NR1: (0.3260.12) VS (0.6760.13),
P=0.004] and Day 7 [t-NR1: (0.6160.06) VS (0.7360.04),
P=0.046; p-NR1: (0.2860.03) VS (0.5760.07), P=0.002] [t-
NR1: (0.6060.04) VS (0.8060.09), P=0.021; p-NR1:
(0.4860.03) VS (0.7760.02), P=0.012].
Discussion
The primary findings of this study are that chronic compression
of the dorsal root ganglia with SURGIFLO
TM induced long-
lasting thermal hyperalgesia and mechanical allodynia, led to
robust increase in IL-b, IL-6 and TNF- a, activated the microglia
and elevated the expression and phosphorylation of NMDA
receptors within the spinal dorsal horn and DRG ipsilateral to
CCD. Intrathecal treatment with spironolactone twice daily on
day 2–4 after CCD surgery markedly improved pain behaviors,
had no effect on pain behavior under inhibition of glial cells by
pre-application of minocycline, down-regulated the expression of
IL-1band TNF-a and inhibited the activation of microglia. The
expression and phosphorylation of NMDA receptor also signifi-
cantly decreased in the spinal dorsal horn and DRG. Nevertheless,
spironolactone exhibited no influence on the expression of IL-6.
Our results suggest that microglia are a source of multiple
cytokines, including IL-1b, IL-6 and TNF-a, which can contribute
to different features of pathological pain. It also confirmed that
microglial cells is not the only source of IL-6. At the same time, IL-
6 can also be derived from other cells, such as astrocytes. Taken
together, we conclude that spironolactone inhibits the activation of
microglia, down-regulates the production of proinflammatory
cytokines as well as inhibits the expression and activation of
NMDA receptors in the spinal dorsal horn and DRG are the main
mechanisms contributing to improving pain behaviors.
Consistent with our previous study, radicular pain hyperexcit-
ability can be alleviated via intrathecal injection of spironolactone
following chronic compression of the dorsal root ganglia [32],
whereas Wang et al. [37,38] reported that spironolactone given
intrathecally had no effects on neuropathic pain after peripheral
nerve injury in rats. This apparent discrepancy probably arises
from the different study models used in the three papers. Studies
suggest that peripheral injury activates glia and leads to the
induction of cytokines and other chemical mediators in glial cells.
Cytokines are then released and act back on neurons to facilitate
central sensitization, activated glial cells are a source of cytokines
[4]. The present study demonstrates interactions between micro-
glia and neurons through proinflammatory cytokines and
NMDAR coupling in central hyperexcitability and inflammatory
hyperalgesia. The expressions of several proinflammatory cyto-
kines, as revealed by western blot experiments in our present
study, are considerably increased following chronic compression of
the dorsal root ganglia. Our previous experiment also revealed
a notable up regulation of Ikb-a in the early stage of radicular pain
[12]. The expression of Ikb-a parallels with NF-kb activity, which
has been proposed to be a reliable marker for cytokine-responsive
cells within the central nervous system [39,40]. While no overt
tissue inflammation and edema occurred at the spinal level
Figure 3. Weston blot and statistical analysis showed the effects of intrathecal injection of spironolactone on activation of
microglia in the spinal dorsal horn (n=3/each). The expression and activation of microglia (OX-42) were significantly up-regulated after CCD
surgery compared with Sham group,
*p,0.01 (A and B). Intrathecal delivery of spironolactone (3 mg) twice a day from Days 2 to 4 subsequent to CCD
surgery significantly inhibited the expression of microglia on Day 4 and Day 7 after CCD surgery,
#p,0.05,
##p,0.01 (A and B).
doi:10.1371/journal.pone.0039897.g003
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dorsal horn, on the contrary, shown marked decrease after
peripheral nerve injury [42]. Moreover, epidural or intrathecal
administration with anti-inflammatory glucocorticoids exerted
beneficial effects on pain behaviors and significantly decreased
the expression of NMDA receptor in the superficial dorsal horn
and DRG after chronic compression of the dorsal root ganglia
[12,13], whereas intrathecal treatment with dexamethasone
exacerbated neuropathic pain behaviors after peripheral nerve
injury [37,38]. Correlated with their study, the expression of
NMDA receptor did not change after intrathecal injection of
spironolactone. These opposing results further confirm that the
anti-inflammatory potency of spironolactone in the superficial
dorsal horn and DRG is implicated in the mechanism for which
beneficial effects on radicular pain behaviors are involved.
A large body of animal and clinical studies also reported that
spironolactone has potent anti-inflammatory effects in multiple
organs and systems via mineralocorticoid receptor or non-
mineralocorticoid receptor mechanisms. For example, first, in
principal cells of the cortical collecting duct, spironolactone
attenuated aldosterone-induced inflammatory cytokines produc-
tion such as IL-1b and IL-6 via mineralocorticoid receptor-
dependent pathway [43], second, in human mononuclear cells,
spironolactone inhibited the activation of NF-kb and the
expression of several NF-kb-targeted genes via non-mineralocor-
ticoid receptor mechanisms [44,45], third, in rheumatoid arthritis
patients, treatment with spironolactone improves both endothelial
dysfunction and inflammatory disease activity [24,27]. In our
present study, we also found a robust anti-inflammatory effect of
spironolactone. However, whether these effects are mineralocor-
ticoid receptor-dependent or non-mineralocorticoid receptor-
relevant need further exploration. Though an in vivo study
showed that spironolactone can reduce the activation of glial cells
through mineralocorticoid receptor dependent pathway [28], the
expression of mineralocorticoid receptors in glial cells in spinal
cord and DRG after CCD surgery remains to be investigated.
Figure 4. Weston blot and statistical analysis showed the effects of intrathecal injection of spironolactone on production of
proinflammatory cytokines in the spinal dorsal horn (n=3/each). After CCD surgery, the expression of IL-1b, IL-6 and TNF-a were
significantly up-regulated compared with Sham group,
*P,0.01 (A and B). Intrathecal injection of spironolactone (3 mg) twice a day from Days 2 to 4
subsequent to CCD surgery significantly reduced the production of IL-1b and TNF-a (A and C) compared with vehicle treated CCD rats,
#P,0.05,
##P,0.01. Spironolactone has no effects on the production of IL-6 compared with vehicle treated CCD rats, P.0.05 (A and C).
doi:10.1371/journal.pone.0039897.g004
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activation, inflammatory cytokine release as well as the expression
andphosphorylationofNMDAreceptoraffectorfacilitateneuronal
plasticity through interactions with mineralocorticoid receptor and
playacriticalroleinthedevelopmentofinflammatoryhyperalgesia,
we studied the effects of mineralocorticoid receptor antagonist
spironolactone. Our results shown that intrathecal injection of
spironolactone significantly down-regulated the expression and
phosyphorylation of NMDA receptors in the spinal dorsal horn and
DRG,whileWangandhiscolleaguesfoundthatspironolactonehad
no effects on the expression of NMDA receptors in the spinal cord.
The anti-inflammatory effect of spironolactone may underlie the
main mechanisms contributing to its inhibitory action on the
expression and phosphorylation of NMDA receptors in the
superficialdorsalhorn.Ourdatashowedthat,asrevealedbywestern
blot experiments, spironolactone significantly down-regulated p-
NR1 and t-NR1 on Day 4 and 7 after CCD surgery. Notably, the
time-course of NMDA receptor expression and phosphorylation
generally parallel that of proinflammatory cytokines, microglia and
pain behaviors changes after intrathecal injection of spironolactone
in rats. Numerous in vitro and in vivo evidences also suggest the
existenceofafunctionalinteractionamongmicroglia,proinflamma-
tory cytokines and NMDA receptors. For example, (1) IL-1b
enhanced NMDA receptor NR1 subunit phosphorylation in the
inflammatory pain models [4] and cancer pain models [10] while
intrathecal injection IL-1 receptor antagonist can alleviate in-
flammatoryhyperalgesiaviapreventingphosphorylationofNMDA
receptor NR1 subunit in rats [11], (2) through activation of tyrosine
kinases and subsequent NR2A/B subunit phosphorylation, IL-1b
cansignificantlyincreasedNMDAreceptorfunctioninhippocampal
neurons[46],(3)recently,TNF-aandIL-1bwereshowntoincrease
AMPA and NMDA-induced currents in lamina II superficial dorsal
horn neurons [3], (4) via sphingomyelin phosphodiesterase 3
pathway, TNF-a can enhance the expression and phosphorylation
of NMDA receptors [47]. Though previous studies shown that the
activation of MRs produce striking facilitation of long-term
potentiation [48], a recent study proved that these effects are
mediated by AMPA receptor but not NMDA receptors [49].
However, under present experiment condition, we can not deny
thedirectmodulationeffectsofspironolactoneontheexpressionand
phosphorylation of NMDA receptors in the spinal cord of radicular
pain rat.
Figure 5. Weston blot and statistical analysis showed the effects of intrathecal injection of spironolactone on production of
proinflammatory cytokines in the DRG (n=3/each). After CCD surgery, the expression of IL-1b, IL-6 and TNF-a were significantly up-regulated
compared with Sham group,
*P,0.01 (A and B). Intrathecal injection of spironolactone (3 mg) twice a day from Days 2 to 4 subsequent to CCD
surgery significantly reduced the production of IL-1b and TNF-a (A and C) compared with vehicle treated CCD rats,
#P,0.05,
##P,0.01.
Spironolactone has no effects on the production of IL-6 compared with vehicle treated CCD rats, P.0.05 (A and C).
doi:10.1371/journal.pone.0039897.g005
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significantly attenuated chronic constriction injury-induced pain
related behaviors and the production of TNF-a in the sciatic nerve
[31]. Our previous studies shown that remarked inflammatory
processes and significant NMDA upregulation also occurred in the
dorsal root ganglion [12]. Intrathecal spironolactone injection may
potentially influence dorsal root ganglion and regions beyond the
targeted spinal segments. However, many previous researches
suggest that intrathecal injection of drugs in a low volume is
a method of regional drug delivery, only effects on homologous
spinal segments [38,50,51]. In our present experiments, IL-1beta,
TNF-alpha, t-NR1 and phosphorylated NR1 are also expressed in
DRG, suggesting a potential role of them in pain processing in the
DRG. Intrathecal administration of spironolactone inhibited the
up-regulation of IL-1beta, TNF-alpha, t-NR1 and phosphorylated
NR1 in the DRG as well as the spinal dorsal horn. So the primary
site of spironolactone action should be within the spinal cord and
DRG in the present experiments.
The present findings may have important implication. Follow-
ing its peripheral anti-inflammatory effects was explored we
further found that spironolactone can significantly inhibits the
activation of microglia, decrease the production of proinflamma-
tory cytokines as well as the expression and phosphorylation of
NMDA receptors at the spinal level. Advancing from previous
studies, the model emphasizes activation of glia by tissue injury,
concomitant cytokine release, and post-translational regulation of
NMDAR through IL-1R signaling. In addition, many clinical
studies had proved that both intravenous and oral spironolactone
is reasonably safe and economically attractive. Spironolactone
may be an ideal anti-inflammatory drug used to treat low back
pain in the near future.
Conclusion
In summary, the present study shown that IL-1beta, TNF-
alpha, t-NR1 and phosphorylated NR1 were involved in
pathogenesis of neuropathic pain not only in the spinal cord but
also in the DRG, and intrathecal delivery of spironolactone has
therapeutic effects on radicular pain induced by chronic
compression of the dorsal root ganglion with SURGIFLO
TM.
Spironolactone inhibits the activation of microglia, down-regulates
the production of IL-1b and TNF-a as well as decreases the
expression and phosyphorylation of NMDA receptors are the
main mechanisms contributing to its beneficial effects. However,
whether spironolactone inhibits the activation of microglia and the
production of proinflammatory cytokines is mineralocorticoid
receptor dependent or not still unknown and whether spirono-
Figure 6. Weston blot and statistical analysis showed the effects of intrathecal injection of spironolactone on the expression and
phosphorylation of NMDAR in the spinal dorsal horn (n=3/each). The expression and phosphorylation of NMDA receptor NR1 subunit (t-
NR1 and p-NR1) were significantly up-regulated after CCD surgery compared with Sham group,
*p,0.01 (A and B). Intrathecal delivery of
spironolactone (3 mg) twice a day from Days 2 to 4 subsequent to CCD surgery significantly inhibited the expression of t-NR1 and p-NR1 on Day 4 and
Day 7 after CCD surgery,
#p,0.05,
##p,0.01 (A and C).
doi:10.1371/journal.pone.0039897.g006
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receptors more than NMDA receptors also need further studies to
investigate.
Methods
Animal Models of Radicular Pain
Adult male Sprague Dawley rats weighing 275–325 g (provided
by the Laboratory Animal Center of Drum Tower Hospital) were
used. The animal room was artificially lighted from 7:00 A.M.
until 7:00 P.M. Rats were housed in individual cages with free
access to water and food pellets. Room temperature was
maintained at 24uC. The experimental protocol was approved
by our Institutional Animal Care and Use Committee. Aseptic
technique was used in all surgical procedures. For CCD operation,
rats had their right L5 DRG/exiting nerve root compressed by
a hemostatic matrix (SURGIFLO
TM) according to the method we
described previously [12]. Briefly, the surgical procedure was
performed aseptically under pentobarbital anesthesia (50 mg/kg
intraperitoneally). Paraspinal muscles were separated from the
mammillary process and the transverse process to expose the right
L5 intervertebral foramen. A stainless 22-G steel needle, with
a blunt angle to avoid tissue penetration, was gently inserted
approximately 4 mm into the L5 intervertebral foramen. The
needle was inserted at a 30–40uangle toward the dorsal middle line
and 10–15ubelow the vertebral horizontal line. Care was taken to
minimize contact with the existing nerve root/DRG by monitor-
ing twitches of ipsilateral hind paw muscles. When small twitches
were noted, the needle was either slightly withdrawn or redirected.
SURGIFLO
TM (60 ml) was slowly injected (within 1–2 min) into
the right L5 intervertebral foramen, which was often accompanied
by one or two mild twitches of ipsilateral hind paw muscles. After
the injection, the muscle and skin layers were closed with 6.0 nylon
sutures. Sham operation was performed following the same
surgical procedure but without the SURGIFLO
TM injection.
The animals were treated with an intraperitoneal injection of
cefuroxime in the prophylactic dose of 20 mg/kg, 2 h pre-
operatively and once a day for the next 2 days to prevent infection.
Intrathecal Catheterization and Drug Delivery
An intrathecal PE10 catheter was implanted in a rat under the
same surgical conditions to the level of the lumbar enlargement
(,8.5 cm from the incision site for this rat age group) according to
the method described previously [33]. Those rats exhibiting
postoperative neurological deficits (e.g., paralysis) or poor groom-
ing were excluded from the experiments. Spironolactone and
minocycline were also purchased from Sigma (St. Louis, MO) and
dissolved in 10% ethanol solution. Spironolactone and minocy-
cline were injected intrathecally in a 10 ml volume followed by
a1 0ml saline flush.
Figure 7. Weston blot and statistical analysis showed the effects of intrathecal injection of spironolactone on the expression and
phosphorylation of NMDAR in the DRG (n=3/each). The expression and phosphorylation of NMDA receptor NR1 subunit (t-NR1 and p-NR1)
were significantly up-regulated after CCD surgery compared with Sham group,
*p,0.01 (A and B). Intrathecal delivery of spironolactone (3 mg) twice
a day from Days 2 to 4 subsequent to CCD surgery significantly inhibited the expression of t-NR1 and p-NR1 on Day 4 and Day 7 after CCD surgery,
#p,0.05,
##p,0.01 (A and C).
doi:10.1371/journal.pone.0039897.g007
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Rats were deeply anesthetized with pentobarbital sodium
(100 mg/kg, i.p.) and perfused transcardially with 4% para-
formaldehyde in 0.1 M phosphate buffer at pH 7.4. The lumbar
spinal cord and the DRG segments were removed, postfixed, and
transferred to 30% sucrose for frozen sections. After washes in
PBS, the sections were blocked for 60 min at room temperature
with 10% (v/v) normal fetal bovine serum (Vector Laboratories,
Peterborough, UK) in PBS. The primary Ab (rabbit polyclonal
anti- OX-42, 1:200, chemicon, CA) was applied, and samples were
then incubated for 48 h at 4uC. After washing, the secondary Ab
(Alexa Fluor 488, 1:500, abcam, CA) was applied, and samples
were further incubated at 4uC overnight. Sections were mounted
on glass slides, air-dried and coverslipped using Aquamount
(Fisher Scientific, Ottawa, Canada). Images were taken at 406,
2006 and 4006 magnification using the Leica TCS SP2
multiphoton confocal microscope (Leica Microsystems, Wetzlar,
Germany).
Western Blot
Rats were killed rapidly by decapitation after anesthesia, Fresh
tissue samples from bilateral L5 DRG and spinal cord dorsal horn
were removed after laminectomy. Lumbar spinal and DRG
segments were divided into the ipsilateral and contralateral side as
well as the dorsal and ventral part and homogenized in an SDS
sample buffer containing a mixture of proteinase inhibitors (Sigma,
USA). Protein samples were separated on SDS-PAGE gel (OX-
42,IL-1 b, IL-6 and TNF-a: 12% gradient gel, t-NR1 and p-NR1:
6% gradient gel) and transferred to polyvinylidene difluoride filters
(Millipore, USA). The filters were blocked with 5% milk and then
immunoblotted using antibodies against OX-42 (Abcam, USA,
1:500 dilution), IL-1 b (Bioworld, USA, 1:400 dilution), IL-6
(Santa cruz, USA, 1:400 dilution), TNF-a (R&D Systems, USA,
1:400 dilution), NR1 (abcam, UK, 1:500 dilution), and NR1
(phospho Ser896) (abcam, UK, 1:500 dilution). The membrane
was washed with TBS and incubated with goat polyclonal
secondary antibody to rabbit IgG (abcam, UK, 1:5000 dilution).
The blots were visualized in ECL solution (DuPont-NEN, USA)
for 1 min and exposed to hyperfilms (Amersham Biosciences) for
1–10 min. The density of specific bands was measured with
a computer-assisted imaging analysis system and normalized
against corresponding loading control bands. b-actin (abcam,
UK, 1:1000 dilution) was used as a loading control for IL-1b, IL-6
and TNF-a, while Na+/K+ ATPase (abcam, UK, 1:500 dilution)
for NR1 and NR1 (phospho Ser896).
Behavioral Tests
Animals were habituated to the test environment daily (a
60 min session) for 3 days before baseline testing. The testing
procedure for thermal hyperalgesia was performed according to
a previously published method [34]. Temperature was set to
achieve baseline latency at 12 s and a cutoff of 25 s. Mechanical
allodynia was examined by applying a von Frey filament to the
plantar surface of each hindpaw [35]. The cut off force was 15 g.
Statistical Analysis
All data are expressed as mean 6SD (standard deviation). Data
from behavioural tests were analyzed by using repeated ANOVA
measurements across testing time points to detect overall
differences among treatment groups. Data from western blot
experiments were analyzed by using One-way ANOVA to
determine differences among all experiment groups. In both cases,
when significant main effects were observed, the LSD post hoc
tests were performed to determine sources of differences.
Differences were considered to be statistically significant at the
level of a=0.05.
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